Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. [electronic resource]
Producer: 20200403Description: e025687 p. digitalISSN:- 2044-6055
- Adult
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Clinical Trials, Phase III as Topic
- Double-Blind Method
- Female
- Humans
- Immunosuppressive Agents -- administration & dosage
- Injections, Subcutaneous
- Lupus Erythematosus, Systemic -- drug therapy
- Male
- Middle Aged
- Multicenter Studies as Topic
- Prednisone -- administration & dosage
- Randomized Controlled Trials as Topic
- Rituximab -- administration & dosage
- Severity of Illness Index
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.